Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
CEO Slosman doubles down with second open-market purchase in 10 months as stock trades well below 52-week highs amid unprofitable fundamentals.
CEO and President Marvin Slosman is making his second open-market purchase at InspireMD in less than a year, acquiring shares at levels well below the company's 52-week highs. The stock has declined significantly over both the prior month and quarter, trading near the lower end of its 52-week range, yet Slosman is committed enough to add to his position. His prior open-market purchase last year was well-timed in the near term, though the longer-term outcome proved negative; this current buy at even lower prices occurs while the company remains unprofitable with recent quarterly losses, though revenue is growing. The timing is notable: three other insiders purchased shares within the same two-week window, creating a cluster of insider buying pressure on the same stock during a period of weakness. For a CEO to keep buying into a distressed valuation and declining stock suggests either conviction in a turnaround or simply opportunistic accumulation at depressed prices.
NSPR CEO Slosman buys 10,330 shares at $2.42 on 7/30; 3 other insiders bought within 14 days—coordinated accumulation amid -$11.2M annual net loss
CEO Marvin Slosman purchased 10,330 shares at $2.42 for $24,998.60, increasing his holdings to 2,420,866 shares. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated activity at InspireMD. The timing is notable given the company's fundamental stress—annual net income was negative ($-11,166,000.00 on revenue of $1,529,000.00 in the latest quarter)—and the stock's recent volatility: it has recovered +20.6% over 30 days but remains -27.3% from its 52-week high of $3.70. The multi-insider purchase pattern in a struggling, unprofitable firm warrants examination of whether this reflects an opportunity thesis or insider response to a pending catalyst not yet public.
